

# PUBLICATIONS CANSEARCH RESEARCH PLATFORM IN ONCOLOGY AND HEMATOLOGY PEDIATRIC (2021-2011)



July 2021, Prof Ansari Geneva university

## 1. ARTICLES ORIGINAUX PUBLIES OU ACCEPTES DANS DES JOURNAUX AVEC POLITIQUE EDITORIALE

2021

1. **V. Mlakar**, P. H. Curtis, M. Armengol, V. Ythier, I. Dupanloup, K. B. Hassine, **L. Lesne**, R. Murr, **S. Mlakar**, **T. Nava**, **M. Ansari**.  
*The analysis of GSTA1 promoter genetic and functional diversity of human populations*  
Sci Rep 2021 Vol. 11 Issue 1 Pages 5038  
Accession Number: 33658540 PMCID: PMC7930039 DOI: 10.1038/s41598-021-83996-2
2. C. Leclercq, F. Toutain, **F. Baleyrier**, A. G. L'Huillier, N. Wagner, C. Lironi, A.M. Calza, **M. Ansari**, G. Blanchard-Rohner.  
*Pediatric Acute B-Cell Lymphoblastic Leukemia Developing Following Recent SARS-CoV-2 Infection*  
J Pediatr Hematol Oncol 2021  
Accession Number: 33480653 DOI: 10.1097/MPH.0000000000002064
3. **Waespe N**, Belle FN, Redmond S, Schindera C, Spycher BD, Rossler J, **Ansari M**, Kuehni CE, Swiss Paediatric Oncology G.  
*Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer - A national cohort study.*  
Eur J Cancer, vol. 145 (2021), No pp. 71-80
4. Seydoux C, Medinger M, Gerull S, Halter J, Heim D, Chalandon Y, Levrat SM, Schanz U, Nair G, **Ansari M**, Simon P, Passweg JR, Cantoni N.  
*Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.*  
Ann Hematol, vol. 100 (2021), No 1, pp. 209-216
5. **Waespe N**, **Strebel S**, **Jurkovic Mlakar S**, Krajcinovic M, Kuehni CE, **Nava T**, **Ansari M**.  
*Genetic Predictors for Sinusoidal Obstruction Syndrome-A Systematic Review.*  
J Pers Med. (2021). Vol. 11, No. 5
6. Remy A, Theoret Y, **Ansari M**, Bittencourt H, Ducruet T, **Nava T**, Pastore Y, Rezgui MA, Krajcinovic M, Kleiber N.  
*Is Busulfan Clearance Different in Patients With Sickle Cell Disease? Let's Clear Up That Case With Some Controls.*  
J Pediatr Hematol Oncol. (2021). Vol. No.
7. Pratt VM, Cavallari LH, Del Tredici AL, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, van Schaik RHN, Whirl-Carrillo M, Weck KE, (dont **Ansari M**).  
*Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and European Society for Pharmacogenomics and Personalized Therapy.*  
J Mol Diagn. (2021). Vol. No.
8. Perez A, van der Louw E, Nathan J, El-Ayadi M, **Golay H**, Korff C, **Ansari M**, Catsman-Berrevoets C, **von Bueren AO**.  
*Ketogenic diet treatment in diffuse intrinsic pontine glioma in children: Retrospective analysis of feasibility, safety, and survival data.*  
Cancer Rep (Hoboken). (2021). Vol. No. pp.e1383

9. **Papangelopoulou D, Ansari M, Bartoli A, Fluss J, von Bueren AO.**  
*Trigeminal nerve chronic motor denervation caused by cerebellar peduncle pilocytic astrocytoma.*  
Childs Nerv Syst. (2021). Vol. 37, No. 4, pp.1035-7
10. **Mlakar V, Morel E, Mlakar SJ, Ansari M, Gumy-Pause F.**  
*A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma.*  
J Exp Clin Cancer Res. (2021). Vol. 40, No. 1, pp.189
11. Lupatsch JE, Kreis C, Konstantinoudis G, **Ansari M**, Kuehni CE, Spycher BD.  
*Birth characteristics and childhood leukemia in Switzerland: a register-based case-control study.*  
Cancer Causes Control. (2021). Vol. 32, No. 7, pp.713-23
12. Iqbal M, Reljic T, Corbacioglu S, de la Fuente J, Gluckman E, Kumar A, Yassine F, Ayala E, El-Jawahri A, Murthy H, Almohareb F, Hashmi SK, Cappelli B, Alahmari A, Scigliuolo GM, Kassim A, Aljurf M, Kharfan-Dabaja MA, (dont **Ansari M**).  
*Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium.*  
Transplant Cell Ther. (2021). Vol. 27, No. 2, pp.167 e1- e12
13. Faulkner L, Verna M, Rovelli A, Agarwal RK, Dhanya R, Parmar L, Sedai A, Kumari A, Ramprakash S, Raghuram CP, Mehta P, Elizabeth S, Khalid S, Batool A, Ghilani SK, Fatima I, Zara T, Marwah P, Soni R, Trivedi D, Conter V, Canesi M, Othman D, Faeq V, Kleinschmidt K, Yesillipek A, Lam CG, Howard SC, Corbacioglu S, Pediatric Diseases Working Party of the European Blood and Marrow Transplantation Group (dont **Ansari M**).  
*Setting up and sustaining blood and marrow transplant services for children in middle-income economies: an experience-driven position paper on behalf of the EBMT PDWP.*  
Bone Marrow Transplant. (2021). Vol. 56, No. 3, pp.536-43
14. **Ansari M**, Petrykey K, Rezgui MA, Del Vecchio V, Cortyl J, Ameer M, **Nava T**, Beaulieu P, St-Onge P, **Mlakar SJ, Uppugunduri CRS**, Theoret Y, Bartelink IH, Boelens JJ, Bredius RGM, Dalle JH, Lewis V, Kangarloo BS, Corbacioglu S, Sinnott D, Bittencourt H, Krajcinovic M.  
*Genetic susceptibility to acute graft versus host disease in pediatric patients undergoing HSCT.*  
Bone Marrow Transplant. (2021). Vol. No.
15. Luana Lavieri, Christa Koenig, Nicole Bodmer, Philipp Agyeman, Katrin Scheinemann, **Marc Ansari**, Roland A Ammann.  
*Predicting Fever in Neutropenia with Safety Relevant Events in Children Undergoing Chemotherapy for Cancer : the Prospective Multicenter SPOG 2015 FN Definition Study.*  
Pediatr Blood Cancer. (2021) , pp. e29253
16. Srinivasamurthy SK, Ashokkumar R, Kodidela S, Howard SC, Samer CF, **Uppugunduri CRS.**  
*Impact of computerised physician order entry (CPOE) on the incidence of chemotherapy-related medication errors: a systematic review.*  
Eur J Clin Pharmacol. (2021). Vol. No.
17. Srinivasamurthy SK, Ashokkumar R, Kodidela S, Howard SC, Samer CF, **Chakradhara Rao US.**  
*Impact of computerised physician order entry (CPOE) on the incidence of chemotherapy-related medication errors: a systematic review.*  
Eur J Clin Pharmacol. (2021). Vol. No.
18. **Bernard F, Uppugunduri CRS**, Meyer S, Cummins M, Patrick K, James B, Skinner R, Tewari S, Carpenter B, Wynn R, Veys P, Amrolia P, UK Paediatric BMT group.  
*Excellent overall and chronic graft-versus-host-disease-free event-free survival in Fanconi anaemia patients undergoing matched related- and unrelated-donor bone marrow transplantation using alemtuzumab-Flu-Cy: the UK experience.*  
Br J Haematol. (2021). Vol. 193, No. 4, pp.804-13
19. **Marc Ansari, Chakradhara Rao Uppugunduri, Patricia Huezo-Diaz Curtis, Tiago Nava, M. Aziz Rezgui, Vid Mlakar, Simona Jurkovic Mlakar, Nicolas Waespe, Yves Théoret, Fabienne Gumy-Pause, Fanette Bernard**, Yves Chalandon, JJ Boelens, R.G.M Bredius, J.H. Dalle, Christa Nath, Selim Corbacioglu, Christina Peters, Peter Bader, Peter Shaw, Henrike Bittencourt, and Maja Krajcinovic.

*Association study of candidate DNA repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem cell transplantation.*

The Pharmacogenomics Journal. April 2021 (Accepté mais pas publié)

20. Rahel Kasteler, Christa Lichtensteiger, Christina Schindera, **Marc Ansari**, Claudia E. Kuehni, for the Swiss Pediatric Oncology Group.  
*Validation of questionnaire-reported chest wall abnormalities with a telephone interview in Swiss childhood cancer survivors.* BMC cancer. June 2021. (Accepté mais pas publié)
21. **Khalil Ben Hassine, Tiago Nava**, Yves Theoret, Christa E. Nath, Youssef Daali, Nastya Kassir, Victor Lewis, Robert G M Bredius, Peter J. Shaw, Henrique Bittencourt, Maja Krajinovic, **Chakradhara Rao Satyanarayana Uppugunduri, Marc Ansari**.  
*Precision dosing of IV busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.* Pharmacometrics & Systems Pharmacology. June 2021. (Accepté mais pas publié)
22. Marianne Ifversen, Luisa Sisinni, Krzysztof Kalwak, Daphna Hutt, Thomas Lehrnbecher, Adriana Balduzzi, Tamara Diesch, Andrea Jarisch, Tayfun Güngör, Jerry Stein, Isaac Yaniv, Halvard Bonig, Michaela Kuhlen, **Marc Ansari, Tiago Nava**, Jean-Hugues Dalle, Cristina Diaz De Heredia, Eugenia Trigos, Ulrike Falkenberg, Mihaela Hartmann, Marco Deiana, Marta Canesi, Chiara Broggi, Alice Bertaina, Brenda Gibson, Gergely Krivan, Kim Vettenranta, Toni Matic, Jochen Buechner, Anita Lawitschka, Christina Peters, Akif Yesilipek, Koray Yalçın, Giovanna Lucchini, Shahrzad Bakhtiar, Dominik Turkiewicz, Rütta Niinimäki, Jacek Wachowiak, Simone Cesaro, Arnaud Dalissier, Selim Corbacioglu, Andre Manfred Willasch, Peter Bader.  
*Supportive care during paediatric haematopoietic stem cell transplantation: prevention of infections. A report from workshops on supportive care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT).* Frontiers in Pediatrics, section Pediatric Oncology. 2021. (Accepté mais pas publié)

## 2020

23. Willasch AM, Peters C, Sedlacek P, Dalle JH, Kitra-Roussou V, Yesilipek A, Wachowiak J, Lankester A, Prete A, Hamidieh AA, Ifversen M, Buechner J, Krivan G, Hamladji RM, Diaz-de-Heredia C, Skorobogatova E, Michel G, Locatelli F, Bertaina A, Veys P, Dupont S, Or R, Gungor T, Aleinikova O, Sufliarska S, Sundin M, Rascon J, Kaare A, Nemet D, Fagioli F, Klingebiel TE, Styczynski J, Bierings M, Nagy K, Abecasis M, Afanasyev B, **Ansari M**, Vettenranta K, Alseraihy A, Chybicka A, Robinson S, Bertrand Y, Kupesiz A, Ghavamzadeh A, Campos A, Pichler H, Dalissier A, Labopin M, Corbacioglu S, Balduzzi A, Galimard JE, Bader P.  
*Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy? A multicenter EBMT-PDWP study* Bone Marrow Transplant, (2020)
24. **Uppugunduri CRS**, Muthukumar J, **Robin S**, Santos-Silva T, **Ansari M**.  
*In silico and in vitro investigations on the protein-protein interactions of glutathione S-transferases with mitogen-activated protein kinase 8 and apoptosis signal-regulating kinase 1.* J Biomol Struct Dyn, vol. (2020), No pp. 1-11
25. Uden T, Bertaina A, Abrahamsson J, **Ansari M**, Balduzzi A, Bourquin JP, Gerhardt C, Bierings M, Hasle H, Lankester A, Mischke K, Moore AS, Nivison-Smith I, Pieczonka A, Peters C, Sedlacek P, Reinhardt D, Stein J, Versluys B, Wachowiak J, Willems L, Zimmermann M, Locatelli F, Sauer MG.  
*Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children.* Br J Haematol, (2020)
26. Strahm B, Loewecke F, Niemeyer CM, Albert M, **Ansari M**, Bader P, Bertrand Y, Burkhardt B, Da Costa LM, Ferster A, Fischer A, Güngör T, Gruhn B, Hainmann I, Kapp F, Lang P, Müller I, Schulz A, Szvetnik A, Wlodarski M, Noellke P, Leblanc T, Dalle JH.  
*Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia.* Blood Adv, vol. 4 (2020), No 8, pp. 1760-1769
27. **Robin SKD, Ansari M, Uppugunduri CRS**.  
*Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases.* J Vis Exp, (2020), No 164

28. Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, Shaw PJ, Staciuk R, Ifversen M, Pichler H, Vettenranta K, Svec P, Aleinikova O, Stein J, Gungor T, Toporski J, Truong TH, Diaz-de-Heredia C, Bierings M, Ariffin H, Essa M, Burkhardt B, Schultz K, Meisel R, Lankester A, **Ansari M**, Schrappe M, Group IS, von Stackelberg A, IntRe ALLSG, Balduzzi A, Group IBSS, Corbacioglu S, Party EPDW, Bader P.  
*Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.*  
J Clin Oncol, vol. (2020), No pp. JCO2002529
29. Otth M, Schindera C, Gungor T, **Ansari M**, Scheinemann K, Belle FN, Latzin P, von der Weid N, Kuehni CE, Swiss Pediatric Oncology G.  
*Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation-a cohort study.*  
Bone Marrow Transplant, (2020)
30. **Nava T**, **Ansari M**, Dalle JH, de Heredia CD, Gungor T, Trigoso E, Falkenberg U, Bertaina A, Gibson B, Jarisch A, Balduzzi A, Boenig H, Krivan G, Vettenranta K, Matic T, Buechner J, Kalwak K, Lawitschka A, Yesilipek A, Lucchini G, Peters C, Turkiewicz D, Niinimaki R, Diesch T, Lehrnbecher T, Sedlacek P, Hutt D, Dalissier A, Wachowiak J, Yaniv I, Stein J, Yalcin K, Sisinni L, Deiana M, Ifversen M, Kuhlen M, Meisel R, Bakhtiar S, Cesaro S, Willasch A, Corbacioglu S, Bader P.  
*Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)*  
Bone Marrow Transplan, vol 55(2020), No 6, pp. 1126-1136
31. Moussaoui D, Benard J, Yaron M, **Bernard F**, Adam C, Vulliamoz N, Bouthors T, Andrey V, **Ansari M**, Girardin C, **Gumy-Pause F**.  
*Hypergonadotropic hypogonadism after ovarian tissue cryopreservation on a 13-year-old female: A case report and review of the literature.*  
J Gynecol Obstet Hum Reprod, vol. 50 (2020), No 2, pp. 102029
32. Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries ACH, van Grotel M, Pluijm SFM, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi AF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, **Ansari M**, Kompis M, van der Pal H, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJE, Beck JD, Elsner S, Am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O, PanCare Lc.  
*Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.*  
Eur J Cancer, vol. 138 (2020), No pp. 212-224
33. Koenig C, Bodmer N, Agyeman PKA, Niggli F, Adam C, **Ansari M**, Eisenreich B, Keller N, Leibundgut K, Nadal D, Roessler J, Scheinemann K, Simon A, Teuffel O, von der Weid NX, Zeller M, Zimmermann K, Ammann RA.  
*39.0°C versus 38.5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trial.*  
Lancet Child Adolesc Health, vol. 4 (2020), No 7, pp. 495-502
34. Hamzic S, Aebi S, Joergler M, Montemurro M, **Ansari M**, Amstutz U, Largiader C.  
*Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.*  
Swiss Med Wkly, vol. 150 (2020), No pp. w20375
35. Haeberle B, Rangaswami A, Krailo M, Czuderna P, Hiyama E, Maibach R, Lopez-Terrada D, Aronson DC, Alaggio R, **Ansari M**, Malogolowkin MH, Perilongo G, O'Neill AF, Trobaugh-Lotrario AD, Watanabe K, Schmid I, von Schweinitz D, Ranganathan S, Yoshimura K, Hishiki T, Tanaka Y, Piao J, Feng Y, Rinaldi E, Saraceno D, Derosa M, Meyers RL.  
*The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic Tumors International Collaboration (CHIC) database.*  
Pediatr Blood Cancer, vol. 67 (2020), No 8, pp. e28350
36. Dilo A, Daali Y, Desmeules J, Chalandon Y, **Uppugunduri CRS**, **Ansari M**.  
*Comparing Dried Blood Spots and Plasma Concentrations for Busulfan Therapeutic Drug Monitoring in Children.*  
Ther Drug Monit, vol. 42 (2020), No 1, pp. 111-117

37. De Clercq E, Rost M, von der Weid N, **Ansari M**, Elger BS.  
*To be or not to be in the social media arena? The perspective of healthcare providers working within adolescent and young adult oncology in Switzerland*  
Int J Adolesc Med Health, (2020)
  
38. Cesaro S, Pillon M, Sauer M, Smiers F, Faraci M, de Heredia CD, Wynn R, Greil J, Locatelli F, Veys P, Uyttebroeck A, Ljungman P, Chevalier P, **Ansari M**, Badell I, Gungor T, Salim R, Tischer J, Tecchio C, Russell N, Chybicka A, Styzynski J, Krivan G, Smith O, Stein J, Afanasyev B, Pochon C, Menconi MC, Bosman P, Mauro M, Tridello G, de Latour RP, Dufour C.  
*Long-term outcome after allogeneic hematopoietic stem cell transplantation for Schwachman-Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT).*  
Bone Marrow Transplant, vol 55(2020), No 9, pp. 1796-1809
  
39. Bradford KL, Liu S, Krajinovic M, **Ansari M**, Garabedian E, Tse J, Wang X, Shaw KL, Gaspar HB, Candotti F, Kohn DB.  
*Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene Therapy.*  
Biol Blood Marrow Transplant, (2020)
  
40. Balduzzi A, Bönig H, Jarisch A, Nava T, **Ansari M**, Cattoni A, Prunotto G, Lucchini G, Krivan G, Matic T, Kalwak K, Yesilipek A, Ifversen M, Svec P, Buechner J, Vettenranta K, Meisel R, Lawitschka A, Peters C, Gibson B, Dalissier A, Corbacioglu S, Willasch A, Dalle JH, Bader P.  
*ABO incompatible graft management in pediatric transplantation.*  
Bone Marrow Transplant, (2020)
  
41. Baenzinger J. RK, Mader L., Harju E., **Ansari M.**, **Waespe N.**, Scheinemann K., Michel G.  
*Post-traumatic stress in parents of childhood cancer survivors and the Swiss general population*  
Journal for Psychosocial Oncology - Research & Practice, vol. 2 (2020), No 3
  
42. **Ansari M**, Petrykey K, Rezgui MA, Del Vecchio V, Cortyl J, Ralph RO, **Nava T**, Beaulieu P, St-Onge P, **Jurkovic Mlakar S**, Huezo-Diaz Curtis P, **Uppugunduri CRS**, **Lesne L**, Theoret Y, Chalandon Y, Bartelink IH, Boelens JJ, Bredius RGM, Dalle JH, Lewis V, Kangarloo BS, Peters C, Sinnott D, Bittencourt H, Krajinovic M, Pediatric Disease Working Party of the European Society for B, Marrow T.  
*Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation.*  
Biol Blood Marrow Transplant, vol. 26 (2020), No 5, pp. 920-927
  
43. de la Fuente J, Gluckman E, Makani J, Telfer P, Faulkner L, Corbacioglu S, Paediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation (dont **Ansari M**).  
*The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing.*  
Lancet Haematol. (2020). Vol. 7, No. 12, pp.e902-e11
  
44. Otth M, Schindera C, Gungor T, **Ansari M**, Scheinemann K, Belle FN, Latzin P, von der Weid N, Kuehni CE, Swiss Pediatric Oncology G.  
*Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation-a cohort study.*  
Bone Marrow Transplant. (2020). Vol. No.
  
45. Xavier S, Kumar S, Ramasamy K, **Chakradhara Rao US**.  
*Indo-Swiss symposium on advances in pharmacogenomic strategies for implementation of personalized medicine.*  
Pharmacogenomics. (2020). Vol. No.
  
46. **von Bueren AO**, Hagel C, Rutkowski S.  
*Cerebrospinal fluid evaluation in adult patients with medulloblastoma.*  
Lancet Oncol. (2020). Vol. 21, No. 3, pp.e120
  
47. Schindera C, Kuehni CE, Pavlovic M, Haegler-Laube ES, Rhyner D, **Waespe N**, Roessler J, Suter T, von der Weid NX.  
*Diagnosing Preclinical Cardiac Dysfunction in Swiss Childhood Cancer Survivors: Protocol for a Single-Center Cohort Study.*  
JMIR Res Protoc. (2020). Vol. 9, No. 6, pp.e17724

48. Ottensmeier H, Schlegel PG, Eyrich M, Wolff JE, Juhnke BO, von Hoff K, Frahsek S, Schmidt R, Faldum A, Fleischhack G, **von Bueren A**, Friedrich C, Resch A, Warmuth-Metz M, Krauss J, Kortmann RD, Bode U, Kuhl J, Rutkowski S.  
*Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment.*  
PLoS One. (2020). Vol. 15, No. 1, pp.e0227693
49. Mynarek M, von Hoff K, Pietsch T, Ottensmeier H, Warmuth-Metz M, Bison B, Pfister S, Korshunov A, Sharma T, Jaeger N, Ryzhova M, Zheludkova O, Golanov A, Rushing EJ, Hasselblatt M, Koch A, Schuller U, von Deimling A, Sahm F, Sill M, Riemenschneider MJ, Dohmen H, Monoranu CM, Sommer C, Staszewski O, Mawrin C, Schittenhelm J, Bruck W, Filipinski K, Hartmann C, Meinhardt M, Pietschmann K, Haberler C, Slavic I, Gerber NU, Grotzer M, Benesch M, Schlegel PG, Deinlein F, **von Bueren AO**, Friedrich C, Juhnke BO, Obrecht D, Fleischhack G, Kwiecien R, Faldum A, Kortmann RD, Kool M, Rutkowski S.  
*Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort.*  
J Clin Oncol. (2020). Vol. 38, No. 18, pp.2028-40
50. Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, Johnson JA, Cavallari LH, Shakhnovich V, Thacker DL, Scott SA, Schwab M, **Uppugunduri CRS**, Formea CM, Franciosi JP, Sangkuhl K, Gaedigk A, Klein TE, Gammal RS, Furuta T.  
*Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.*  
Clin Pharmacol Ther. (2020). Vol. No.
51. Kodidela S, Dorababu P, Thakkar DN, Dubashi B, Sundaram R, Muralidharan N, Nidanapu RP, Aribandi A, Pradhan SC, **Uppugunduri CRS**.  
*Association of NUDT15\*3 and FPGS 2572C>T Variants with the Risk of Early Hematologic Toxicity During 6-MP and Low-Dose Methotrexate-Based Maintenance Therapy in Indian Patients with Acute Lymphoblastic Leukemia.*  
Genes (Basel). (2020). Vol. 11, No. 6,
52. Junger ST, Andreiuolo F, Mynarek M, Wohlers I, Rahmann S, Klein-Hitpass L, Dorner E, Zur Muhlen A, Velez-Char N, von Hoff K, Warmuth-Metz M, Kortmann RD, Timmermann B, **von Bueren A**, Rutkowski S, Pietsch T.  
*CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort.*  
Acta Neuropathol. (2020). Vol. 140, No. 3, pp.405-7
53. Junger ST, Andreiuolo F, Mynarek M, Dorner E, Zur Muhlen A, Rutkowski S, **von Bueren AO**, Pietsch T.  
*Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome.*  
Childs Nerv Syst. (2020). Vol. No.
54. Duan L, Renzi S, Weidman D, **Waespe N**, Chami R, Manson D, Cada M, Carcao M.  
*Sirolimus Treatment of an Infant With Intrathoracic Kaposiform Hemangioendothelioma Complicated by Life-threatening Pleural and Pericardial Effusions.*  
J Pediatr Hematol Oncol. (2020). Vol. 42, No. 1, pp.74-8
55. Adam C, Deffert C, Leyvraz C, Primi MP, Simon JP, Beck Popovic M, Benard J, Bouthors T, Girardin C, Streuli I, Vulliemoz N, **Gumy-Pause F**.  
*Use and Effectiveness of Sperm Cryopreservation for Adolescents and Young Adults: A 37-Year Bivalent Experience.*  
J Adolesc Young Adult Oncol. (2020). Vol. No.

## 2019

56. Weiss A, Sommer G, Schindera C, Wengenroth L, Karow A, Diezi M, Michel G, Kuehni CE, Swiss paediatric oncology group (SPOG) (dont **Ansari M**).  
*Hearing loss and quality of life in survivors of paediatric CNS tumours and other cancers.*  
Qual Life Res, vol. 28 (2019), No 2, pp. 515-521
57. Sommer G, Schindler M, Redmond S, Pfeiffer V, Konstantinoudis G, Ammann RA, **Ansari M**, Hengartner H, Michel G, Kuehni CE, Swiss Paediatric Oncology Group.  
*Temporal trends in incidence of childhood cancer in Switzerland, 1985-2014.*  
Cancer Epidemiol, vol. 61 (2019), No pp. 157-164

58. Sipeky C, Llerena A, Manolopoulos VG, Pearson E, **Mlakar V**, Gozzo L, Simmaco M, Marchetti P, Re MD, Stankovic S, Meyer U, Cascorbi I, Ingelman-Sundberg M, Suarez-Kurtz G, Marc J, Katsila T, Paulmichl M, Nofziger C, **Ansari M**, Drago F, van Schaik RH.  
*4th ESPT Conference: pharmacogenomics and personalized medicine - research progress and clinical implementation.*  
Pharmacogenomics, vol. 20 (2019), No 15, pp. 1063-1069
  
59. Perez A, Merlini L, El-Ayadi M, Korff C, **Ansari M, von Bueren AO.**  
*Comment on: Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: A safety and feasibility study.*  
Pediatr Blood Cancer, vol. 66 (2019), No 7, pp. e27664
  
60. **Mlakar V**, Marc J, Manolopoulos VG, Cascorbi I, Stankovic S, Llerena A, Simmaco M, Visvikis-Siest S, Amstutz U, Sipeky C, Meyer UA, Meier-Abt P, van Schaik RH, **Ansari M.**  
*4th ESPT summer school: precision medicine and personalised health.*  
Pharmacogenomics, vol. 20 (2019), No 7, pp. 471-474
  
61. **Mlakar V, Jurkovic Mlakar S, Lesne L, Marino D**, Rathi KS, Maris JM, **Ansari M, Gumy-Pause F.**  
*PRIMA-1(MET)-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level.*  
J Exp Clin Cancer Res, vol. 38 (2019), No 1, pp. 69
  
62. Karas Kuzelicki N, Prodan Zitnik I, Gurwitz D, Llerena A, Cascorbi I, Siest S, Simmaco M, **Ansari M**, Pazzagli M, Di Resta C, Brandslund I, Schwab M, Vermeersch P, Lunshof JE, Dedoussis G, Flordellis CS, Fuhr U, Stingl JC, van Schaik RH, Manolopoulos VG, Marc J.  
*Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey.*  
Pharmacogenomics, vol. 20 (2019), No 9, pp. 643-657
  
63. **Golay H, Jurkovic Mlakar S, Mlakar V, Nava T, Ansari M.**  
*The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation : A Systematized Review.*  
Int J Mol Sci, vol. 20 (2019), No 16
  
64. El-Ayadi M, **Ansari M**, Kuhnol CD, Bendel A, Sturm D, Pietsch T, Kramm CM, **von Bueren AO.**  
*Occurrence of high-grade glioma in Noonan syndrome : Report of two cases.*  
Pediatr Blood Cancer, vol. (2019), No pp. e27625
  
65. De Clercq E, Rost M, Rakic M, **Ansari M**, Brazzola P, Wangmo T, Elger BS.  
*The conceptual understanding of pediatric palliative care: a Swiss healthcare perspective.*  
BMC Palliat Care, vol. 18 (2019), No 1, pp. 55
  
66. Ceppi F, Renella R, Diezi M, **Ansari M**, Duchosal MA, Arber C, Kandalaft L, Coukos G, Beck-Popovic M.  
*Recent advances and future directions in CAR-T cell therapy in pediatric oncology*  
Rev Med Suisse, vol. 15 (2019), No N degrees 632-633, pp. 85-91
  
67. Calinescu AM, Karam O, Wilde JCH, **Ansari M**, McLin VA, Wildhaber BE.  
*International survey on anticoagulation and antiplatelet strategies after pediatric liver transplantation*  
Pediatr Transplant, vol. 23 (2019), No 1, pp. e13317
  
68. Buhler S, Bettens F, Dantin C, Ferrari-Lacraz S, **Ansari M**, Mamez AC, Masouridi-Levrat S, Chalandon Y, Villard J.  
*Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation.*  
Leukemia, (2019)
  
69. Belle FN, Schindera C, Guessous I, Popovic MB, **Ansari M**, Kuehni CE, Bochud M.  
*Sodium and Potassium Intakes and Cardiovascular Risk Profiles in Childhood Cancer Survivors: The SCCSS-Nutrition Study.*  
Nutrients, vol. 12 (2019), No 1
  
70. Belle FN, Beck Popovic M, **Ansari M**, Otth M, Kuehni CE, Bochud M.  
*Nutritional Assessment of Childhood Cancer Survivors (the Swiss Childhood Cancer Survivor Study-Nutrition) : Protocol for a Multicenter Observational Study.*  
JMIR Res Protoc, vol. 8 (2019), No 11, pp. e14427
  
71. **Baleyrier F**, Ranza E, Schappi M, Rougemont AL, Merlini L, **Ansari M**, Blanchard-Rohner G.  
*Activated Phosphoinositide 3 Kinase Delta Syndrome (APDS): A Primary Immunodeficiency Mimicking Lymphoma.*

72. Sommer C, **Gumy Pause F**, Diezi M, Rougemont AL, Wildhaber BE.  
*A National Long-Term Study of Neuroendocrine Tumors of the Appendix in Children: Are We Too Aggressive?*  
Eur J Pediatr Surg. (2019). Vol. 29, No. 5, pp.449-57
73. Saiji E, **Gumy-Pause F**, Lascombes P, Cerato Biderbost C, Marq NL, Berczy M, Merlini L, Rougemont AL.  
*IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis.*  
Virchows Arch. (2019). Vol. 475, No. 5, pp.625-36
74. Pfaff E, El Damaty A, Balasubramanian GP, Blattner-Johnson M, Worst BC, Stark S, Witt H, Pajtler KW, van Tilburg CM, Witt R, Milde T, Jakobs M, Fiesel P, Fruhwald MC, Hernaiz Driever P, Thomale UW, Schuhmann MU, Metzler M, Bochennek K, Simon T, Durken M, Karremann M, Knirsch S, Ebinger M, **von Bueren AO**, Pietsch T, Herold-Mende C, Reuss DE, Kiening K, Lichter P, Eggert A, Kramm CM, Pfister SM, Jones DTW, Bachli H, Witt O.  
*Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.*  
Eur J Cancer. (2019). Vol. 114, No. pp.27-35
75. **Nava T**, Dube E, Gauthier J, Vezina C, Bonnefoy A, Lillicrap D, Rivard GE.  
*Challenges in diagnosis of von Willebrand disease in the presence of combined mutations of different genes.*  
Haemophilia. (2019). Vol. 25, No. 2, pp.e113-e7
76. Kasteler R, Belle F, Schindera C, Barben J, **Gumy-Pause F**, Tinner EM, Kuehni CE, Swiss Pediatric Oncology Group.  
*Prevalence and reasons for smoking in adolescent Swiss childhood cancer survivors.*  
Pediatr Blood Cancer. (2019). Vol. 66, No. 1, pp.e27438
77. Junger ST, Mynarek M, Wohlers I, Dorner E, Muhlen AZ, Velez-Char N, von Hoff K, Rutkowski S, Warmuth-Metz M, Kortmann RD, Timmermann B, Rahmann S, Klein-Hitpass L, **von Bueren AO**, Pietsch T.  
*Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort.*  
Acta Neuropathol Commun. (2019). Vol. 7, No. 1, pp.181
78. **Gumy-Pause F**, Tinner EM, Diezi M, Bergsträsser E, Hengartner H, Eisenreich B, Brazzola P, von der Weid N, Z. T, Scheinemann K.  
*Long-term follow-up after childhood cancer in Switzerland: a position statement from the pediatric Swiss LTFU working group.*  
Bulletin suisse du cancer. (2019). Vol. 39, No. pp.212-5
79. El-Khouly FE, Veldhuijzen van Zanten SEM, Santa-Maria Lopez V, Hendrikse NH, Kaspers GJL, Loizos G, Sumerauer D, Nysom K, Pruunsild K, Pentikainen V, Thorarinsdottir HK, Rutkauskiene G, Calvagna V, Drogosiewicz M, Dragomir M, Deak L, Kitanovski L, **von Bueren AO**, Kebudi R, Slave I, Jacobs S, Jadrijevic-Cvrlje F, Entz-Werle N, Grill J, Kattamis A, Hauser P, Pears J, Biassoni V, Massimino M, Lopez Aguilar E, Torsvik IK, Joao Gil-da-Costa M, Kumirova E, Cruz-Martinez O, Holm S, Bailey S, Hayden T, Thomale UW, Janssens GOR, Kramm CM, van Vuurden DG.  
*Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?*  
J Neurooncol. (2019). Vol. 145, No. 1, pp.177-84
80. Ali S, Krueger J, Richardson SE, Sung L, **Waespe N**, Renzi S, Chiang K, Allen U, Ali M, Schechter T.  
*The yield of monitoring adenovirus in pediatric hematopoietic stem cell transplant patients.*  
Pediatr Hematol Oncol. (2019). Vol. 36, No. 3, pp.161-72

## 2018

81. Zimmermann K, Cignacco E, Engberg S, Ramelet AS, von der Weid N, Eskola K, Bergsträsser E, Consortium P, **Ansari M**, Aebi C, Baer R, Popovic MB, Bernet V, Brazzola P, Bucher HU, Buder R,



- Cagnazzo S, Dinten B, Dorsaz A, Elmer F, Enriquez R, Fahrni-Nater P, Finkbeiner G, Frey B, Frey U, Greiner J, Hassink RI, Keller S, Kretschmar O, Kroell J, Laubscher B, Leibundgut K, Malaer R, Meyer A, Stuessi C, Nelle M, Neuhaus T, Niggli F, Perrenoud G, Pfammatter JP, Plecko B, Rupf D, Sennhauser F, Stade C, Steinlin M, Stoffel L, Thomas K, Vonarburg C, von Vigier R, Wagner B, Wieland J, Wernz B. *Patterns of paediatric end-of-life care: a chart review across different care settings in Switzerland*. *BMC Pediatr*, vol. 18 (2018), No 1, pp. 67
82. Yaniv I, Krauss AC, Beohou E, Dalissier A, Corbacioglu S, Zecca M, Afanasyev BV, Berger M, Diaz MA, Kalwak K, Sedlacek P, Varotto S, Peters C, Bader P, EBMT PWD (dont **Ansari M**). *Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study*. *Biol Blood Marrow Transplant*, vol. 24 (2018), No 8, pp. 1629-1642
  83. Weiss A, Kuonen R, Brockmeier H, Grotzer M, Candreia C, Maire R, Senn P, Stieger C, Rosenfeld J, Veraguth D, Kompis M, Scheinemann K, Kuehni CE, for Swiss Pediatric Oncology Group (SPOG) (dont **Ansari M**). *Audiological monitoring in Swiss childhood cancer patients*. *Pediatr Blood Cancer*, vol. 65 (2018), No 3, pp.
  84. Tyagi AK, **Khoshbeen MB**, Curtis PH, **Uppugunduri CRS**, **Ansari M**. *Development and validation of an allele-specific PCR assay for genotyping a promoter and exonic single nucleotide polymorphisms of MGMT gene*. *J Biol Methods*, vol. 5 (2018), No 2, pp. e92
  85. Simonetta F, Masouridi-Levrat S, Beauverd Y, Tsopra O, Tirefort Y, Koutsi A, Stephan C, Polchlopek-Blasiak K, Pradier A, Dantin C, **Ansari M**, Roosnek E, Chalandon Y. *Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation*. *Leuk Lymphoma*, vol. 59 (2018), No 3, pp. 590-600
  86. Rost M, Acheson E, Kuhne T, **Ansari M**, Pacurari N, Brazzola P, Niggli F, Elger BS, Wangmo T. *Palliative care in Swiss pediatric oncology settings: a retrospective analysis of medical records*. *Support Care Cancer*, vol. 26 (2018), No 8, pp. 2707-2715
  87. Rock N, **Ansari M**, Villard J, Ferrari-Lacraz S, Waldvogel S, McLin VA. *Factors associated with immune hemolytic anemia after pediatric liver transplantation*. *Pediatr Transplant*, vol. 22 (2018), No 5, pp. e13230
  88. Paviglianiti A, Dalle JH, Ayas M, Boelens JJ, Volt F, Iori AP, de Souza MP, Diaz MA, Michel G, Locatelli F, Jubert C, Yakoub-Agha I, Bittencourt H, Bertrand Y, Kenzey C, Tozatto Maio K, Hayashi H, Rocha V, Bader P, Gluckman E, Ruggeri A, EBMT PWD (dont **Ansari M**). *Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party*. *Biol Blood Marrow Transplant*, vol. 24 (2018), No 4, pp. 799-805
  89. Passweg JR, Baldomero H, **Ansari M**, Baerlocher GM, Bargetzi M, Chalandon Y, Duchosal MA, Gerull S, Gungor T, Halter JP, Heim D, Hess U, Leibundgut K, Masouridi-Levrat S, Muller A, Nair G, Pabst T, Renner C, Schmidt A, Stussi G, Nicoloso de Faveri G, Schanz U, for The Swiss Blood Stem Cell Transplantation Group (SBST). *Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016*. *Swiss Med Wkly*, vol. 148 (2018), No pp. w14589
  90. **Nava T**, Kassir N, Rezgui MA, **Uppugunduri CRS**, **Huezo-Diaz Curtis P**, Duval M, Theoret Y, Daudt LE, Litalien C, **Ansari M**, Krajcinovic M, Bittencourt H. *Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation*. *Br J Clin Pharmacol*, vol. 84 (2018), No 7, pp. 1494-1504
  91. Kasteler R, Weiss A, Schindler M, Sommer G, Latzin P, von der Weid NX, Ammann RA, Kuehni CE, Swiss Pediatric Oncology Group (SPOG) (dont **Ansari M**). *Long-term pulmonary disease among Swiss childhood cancer survivors*.

Pediatr Blood Cancer, vol. 65 (2018), No 1

92. Kasteler R, Kam LMH, Weiss A, **Waespe N**, Sommer G, Singer F, von der Weid NX, **Ansari M**, Kuehni CE, Swiss Pediatric Oncology Group.  
*Monitoring pulmonary health in Swiss childhood cancer survivors.*  
Pediatr Blood Cancer, vol. 65 (2018), No 10, pp. e27255
93. **Huezo-Diaz Curtis P**, **Uppugunduri CRS**, Muthukumaran J, Rezgui MA, Peters C, Bader P, Duval M, Bittencourt H, Krajinovic M, **Ansari M**.  
*Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation.*  
Pharmacogenomics J, vol. 18 (2018), No 1, pp. 64-69
94. El-Ayadi M, Egervari K, Merkler D, McKee TA, **Gumy-Pause F**, Stichel D, Capper D, Pietsch T, **Ansari M**, **von Bueren AO**.  
*Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma : A Case Report.*  
Front Neurol, vol. 9 (2018), No pp. 398
95. Corbacioglu S, Carreras E, **Ansari M**, Balduzzi A, Cesaro S, Dalle JH, Dignan F, Gibson B, Guengoer T, Gruhn B, Lankester A, Locatelli F, Pagliuca A, Peters C, Richardson PG, Schulz AS, Sedlacek P, Stein J, Sykora KW, Toporski J, Trigoso E, Vetteranta K, Wachowiak J, Wallhult E, Wynn R, Yaniv I, Yesilipek A, Mohty M, Bader P.  
*Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.*  
Bone Marrow Transplant, vol. 53 (2018), No 2, pp. 138-145
96. **Choong E**, **Uppugunduri CRS**, **Marino D**, Kuntzinger M, Doffey-Lazeyras F, Lo Piccolo R, Chalandon Y, Peters C, Daali Y, **Ansari M**.  
*Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance.*  
Ther Drug Monit, vol. 40 (2018), No 1, pp. 84-92
97. Chatzis O, Darbre S, Pasquier J, Meylan P, Manuel O, Aubert JD, Beck-Popovic M, Masouridi-Levrat S, **Ansari M**, Kaiser L, Posfay-Barbe KM, Asner SA.  
*Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study.*  
BMC Infect Dis, vol. 18 (2018), No 1, pp. 111
98. Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, **Ansari M**, Rechnitzer C, Veal GJ, Covezzoli A, Brugieres L, Perilongo G, Czauderna P, Morland B, Neuwelt EA.  
*Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.*  
N Engl J Med, vol. 378 (2018), No 25, pp. 2376-2385
99. Bovero M, Giacomo C, **Ansari M**, Roulin MJ.  
*Role of advanced nurse practitioners in the care pathway for children diagnosed with leukemia.*  
Eur J Oncol Nurs, vol. 36 (2018), No pp. 68-74
100. Benadiba J, **Ansari M**, Krajinovic M, Vachon MF, Duval M, Teira P, Cellot S, Bittencourt H.  
*Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.*  
PLoS One, vol. 13 (2018), No 4, pp. e0193862
101. Arni D, Wildhaber BE, McLin V, Rimensberger PC, **Ansari M**, Fontana P, Karam O.  
*Effects of plasma transfusions on antithrombin levels after paediatric liver transplantation.*  
Vox Sang, vol. (2018), No pp.
102. **Ansari M**, Gordon E.  
*Le Cancer de l'Enfant et Adolescent. J'ai envie de comprendre.*  
Planète Santé 2018.
103. **von Bueren AO**, Karremann M, Gielen GH, Benesch M, Fouladi M, van Vuurden DG, van Zanten S, Hoffman LM, Kramm CM.  
*A suggestion to introduce the diagnosis of "diffuse midline glioma of the pons, H3 K27 wildtype (WHO grade IV)".*  
Acta Neuropathol. (2018). Vol. 136, No. 1, pp.171-3

104. Seidel C, **von Bueren AO**, Bojko S, Hoffmann M, Pietsch T, Gielen GH, Warmuth-Metz M, Bison B, Kortmann RD, Kramm CM.  
*Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatin-based polychemotherapy regimen: Acute toxicity in pediatric high-grade glioma patients.*  
Strahlenther Onkol. (2018). Vol. 194, No. 3, pp.215-24
105. **Nava T**, Rivard GE, Bonnefoy A.  
*Challenges on the diagnostic approach of inherited platelet function disorders: Is a paradigm change necessary?*  
Platelets. (2018). Vol. 29, No. 2, pp.148-55
106. Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, Bison B, Claviez A, van Vuurden DG, **von Bueren AO**, Gessi M, Kuhnle I, Hans VH, Benesch M, Sturm D, Kortmann RD, Waha A, Pietsch T, Kramm CM.  
*Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.*  
Neuro Oncol. (2018). Vol. 20, No. 1, pp.123-31
107. Janssens GO, Kramm CM, **von Bueren AO**.  
*Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?*  
J Neurooncol. (2018). Vol. 139, No. 2, pp.501
108. Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, Baugh J, Chaney B, Hoffmann M, Lane A, Fuller C, Miles L, Hawkins C, Bartels U, Bouffet E, Goldman S, Leary S, Foreman NK, Packer R, Warren KE, Broniscer A, Kieran MW, Minturn J, Comito M, Broxson E, Shih CS, Khatua S, Chintagumpala M, Carret AS, Escorza NY, Hassall T, Ziegler DS, Gottardo N, Dholaria H, Doughman R, Benesch M, Drissi R, Nazarian J, Jabado N, Boddaert N, Varlet P, Giraud G, Castel D, Puget S, Jones C, Hulleman E, Modena P, Giagnacovo M, Antonelli M, Pietsch T, Gielen GH, Jones D'TW, Sturm D, Pfister SM, Gerber NU, Grotzer MA, Pfaff E, **von Bueren AO**, Hargrave D, Solanki GA, Jadrijevic Cvrlje F, Kaspers GJL, Vandertop WP, Grill J, Bailey S, Biassoni V, Massimino M, Calmon R, Sanchez E, Bison B, Warmuth-Metz M, Leach J, Jones B, van Vuurden DG, Kramm CM, Fouladi M.  
*Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report from the International and European Society for Pediatric Oncology DIPG Registries.*  
J Clin Oncol. (2018). Vol. 36, No. 19, pp.1963-72
109. Baenziger J, Roser K, Mader L, Christen S, Kuehni CE, **Gumy-Pause F**, Tinner EM, Michel G.  
*Can the theory of planned behavior help explain attendance to follow-up care of childhood cancer survivors?*  
Psychooncology. (2018). Vol. 27, No. 6, pp.1501-8
110. Ashokkumar R, Srinivasamurthy S, Kelly J, Howard S, Parasuraman S, **Uppugunduri CR**.  
*Frequency of chemotherapy medication errors: A systematic review.*  
Journal of Pharmacology and Pharmacotherapeutics. (2018). Vol. No. pp.86-91

## 2017

111. Yeates L, Slatter MA, Bonanomi S, Lim F, Ong SY, Dalissier A, Barberi W, Shulz A, Duval M, Heilmann C, Willekens A, Hwang WHY, Uderzo C, Bader P, Gennery AR, EBMT PWD (dont **Ansari M**).  
*Use of defibratide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation.*  
Bone Marrow Transplant, vol. 52 (2017), No 5, pp. 762-764
112. Weiss A, Sommer G, Kuonen R, Scheinemann K, Grotzer M, Kompis M, Kuehni CE, Swiss Paediatric Oncology Group (SPOG) (dont **Ansari M**).  
*Validation of questionnaire-reported hearing with medical records: A report from the Swiss Childhood Cancer Survivor Study.*  
PLoS One, vol. 12 (2017), No 3, pp. e0174479
113. Weiss A, Sommer G, Kasteler R, Scheinemann K, Grotzer M, Kompis M, Kuehni CE, Swiss Pediatric Oncology Group (SPOG) (dont **Ansari M**).  
*Long-term auditory complications after childhood cancer: A report from the Swiss Childhood Cancer Survivor Study.*  
Pediatr Blood Cancer, vol. 64 (2017), No 2, pp. 364-373
114. Wangmo T, De Clercq E, Ruhe KM, Beck-Popovic M, Rischewski J, Angst R, **Ansari M**, Elger BS.  
*Better to know than to imagine: Including children in their health care.*  
AJOB Empir Bioeth, vol. 8 (2017), No 1, pp. 11-20

115. Visvikis-Siest S, Aldasoro Arguinano AA, Stathopoulou M, Xie T, Petrelis A, Weryha G, Froguel P, Meier-Abt P, Meyer UA, Mlakar V, **Ansari M**, Papassotiropoulos A, Dedoussis G, Pan B, Buhlmann RP, Noyer-Weidner M, Dietrich PY, Van Schaik R, Innocenti F, Marz W, Bekris LM, Deloukas P.  
*8th Santorini Conference: Systems medicine and personalized health and therapy, Santorini, Greece, 3-5 October 2016.*  
Drug Metab Pers Ther, vol. 32 (2017), No 2, pp. 119-127
116. **Uppugunduri CRS**, Storelli F, **Mlakar V**, **Huezo-Diaz Curtis P**, Rezgui A, Theoret Y, **Marino D**, Doffey-Lazeyras F, Chalandon Y, Bader P, Daali Y, Bittencourt H, Krajinovic M, **Ansari M**.  
*The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation.*  
Front Pharmacol, vol. 8 (2017), No pp. 451
117. Spycher BD, Lupatsch JE, Huss A, Rischewski J, Schindera C, Spoerri A, Vermeulen R, Kuehni CE, for the Swiss Paediatric Oncology Group and the Swiss National Cohort Study Group (dont **Ansari M**).  
*Parental occupational exposure to benzene and the risk of childhood cancer: A census-based cohort study.*  
Environ Int, vol. 108 (2017), No pp. 84-91
118. Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z, Burman J, Moore J, Rovira M, Wulffraat NM, Kazmi M, Greco R, Snarski E, Kozak T, Kirgizov K, Alexander T, Bader P, Saccardi R, Farge D, European Society for Blood and Marrow Transplantation (EBMT), Autoimmune Diseases Working Party (ADWP), EBMT Paediatric Working Party (PWP), Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT), EBMT (JACIE), EBMT PWD (dont **Ansari M**).  
*Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases.*  
Blood Adv, vol. 1 (2017), No 27, pp. 2742-2755
119. Simonin M, Dalissier A, Labopin M, Willasch A, Zecca M, Mouhab A, Chybicka A, Balduzzi A, Volin L, Peters C, Bader P, Dalle JH, on behalf of PDWP-EBMT (dont **Ansari M**).  
*More chronic GVHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Working Party.*  
Bone Marrow Transplant, vol. 52 (2017), No 7, pp. 1071-1073
120. Schindler M, Belle FN, Grotzer MA, von der Weid NX, Kuehni CE, Swiss Paediatric Oncology Group (SPOG) (dont **Ansari M**).  
*Childhood cancer survival in Switzerland (1976-2013) : Time-trends and predictors.*  
Int J Cancer, vol. 140 (2017), No 1, pp. 62-74
121. Rueegg CS, Gianinazzi ME, Michel G, Zwahlen M, von der Weid NX, Kuehni CE, the Swiss Paediatric Oncology Group (SPOG) (dont **Ansari M**).  
*No evidence of response bias in a population-based childhood cancer survivor questionnaire survey - Results from the Swiss Childhood Cancer Survivor Study.*  
PLoS One, vol. 12 (2017), No 5, pp. e0176442
122. Rost M, Wangmo T, Niggli F, Hartmann K, Hengartner H, **Ansari M**, Brazzola P, Rischewski J, Beck-Popovic M, Kuhne T, Elger BS.  
*Parents' and Physicians' Perceptions of Children's Participation in Decision-making in Paediatric Oncology: A Quantitative Study.*  
J Bioeth Inq, vol. 14 (2017), No 4, pp. 555-565
123. **Nava T**, Rezgui MA, **Uppugunduri CRS**, **Curtis PH**, Theoret Y, Duval M, Daudt LE, **Ansari M**, Krajinovic M, Bittencourt H.  
*GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation.*  
Biol Blood Marrow Transplant, vol. 23 (2017), No 11, pp. 1918-1924
124. **Mlakar V**, **Jurkovic Mlakar S**, Lopez G, Maris JM, **Ansari M**, **Gumy-Pause F**.  
*11q deletion in neuroblastoma: a review of biological and clinical implications.*  
Mol Cancer, vol. 16 (2017), No 1, pp. 114
125. Meyers RL, Maibach R, Hiyama E, Haberle B, Krailo M, Rangaswami A, Aronson DC, Malogolowkin MH, Perilongo G, von Schweinitz D, **Ansari M**, Lopez-Terrada D, Tanaka Y, Alaggio R, Leuschner I, Hishiki T, Schmid I, Watanabe K, Yoshimura K, Feng Y, Rinaldi E, Saraceno D, Derosa M, Czauderna P.

126. Marquardt L, Lacour M, Hoernes M, Opitz L, Lecca R, Volkmer B, Reichenbach J, Hohl D, **Ansari M**, Ozsahin H, Gungor T, Pachlopnik Schmid J.  
*Unusual dermatological presentation and immune phenotype in SCID due to an IL7R mutation: the value of whole-exome sequencing and the potential benefit of newborn screening.*  
J Eur Acad Dermatol Venereol, vol. 31 (2017), No 3, pp. e147-e148
127. Gluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, Carreras J, Pinto Simoes B, Ferster A, Dupont S, de la Fuente J, Dalle JH, Zecca M, Walters MC, Krishnamurti L, Bhatia M, Leung K, Yanik G, Kurtzberg J, Dhedin N, Kuentz M, Michel G, Apperley J, Lutz P, Neven B, Bertrand Y, Vannier JP, Ayas M, Cavazzana M, Matthes-Martin S, Rocha V, Elayoubi H, Kenzey C, Bader P, Locatelli F, Ruggeri A, Eapen M, on behalf of Eurocord, the Pediatric Working Party of the European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research, EBMT PWD (dont **Ansari M**).  
*Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.*  
Blood, vol. 129 (2017), No 11, pp. 1548-1556
128. El-Ayadi M, **Ansari M**, Sturm D, Gielen GH, Warmuth-Metz M, Kramm CM, **von Bueren AO**.  
*High-grade glioma in very young children: a rare and particular patient population.*  
Oncotarget, vol. 8 (2017), No 38, pp. 64564-64578
129. El-Ayadi M, **Ansari M**, Kühnöl CD, Bendel A, Sturm D, Pietsch T, Kramm CM, **von Bueren AO**.  
*Noonan syndrome can be associated with high grade glioma; report of two cases and review of literature.*  
Neuro-Oncology vol. 19 (2017), No 6, pp. 72
130. Dalle JH, Lucchini G, Balduzzi A, Ifversen M, Jahnukainen K, Macklon KT, Ahler A, Jarisch A, **Ansari M**, Beohou E, Bresters D, Corbacioglu S, Dalissier A, Diaz de Heredia Rubio C, Diesch T, Gibson B, Klingebiel T, Lankester A, Lawitschka A, Moffat R, Peters C, Poirot C, Saenger N, Sedlacek P, Trigosso E, Vetterranta K, Wachowiak J, Willasch A, von Wolff M, Yaniv I, Yesilipek A, Bader P.  
*State-of-the-art fertility preservation in children and adolescents undergoing haematopoietic stem cell transplantation : a report on the expert meeting of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) in Baden, Austria, 29-30 September 2015.*  
Bone Marrow Transplant, vol. 52 (2017), No 7, pp. 1029-1035
131. Burman J, Kirgizov K, Carlson K, Badoglio M, Mancardi GL, De Luca G, Casanova B, Ouyang J, Bembeeva R, Haas J, Bader P, Snowden J, Farge D, EBMT PWD (dont **Ansari M**).  
*Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT).*  
Bone Marrow Transplant, vol. 52 (2017), No 8, pp. 1133-1137
132. Belle F, Wengenroth L, Weiss A, Sommer G, Beck Popovic M, **Ansari M**, Bochud M, Kuehni C.  
*Low adherence to dietary recommendations in adult childhood cancer survivors.*  
Clin Nutr, vol. 36 (2017), No 5, pp. 1266-1274
133. Baumann P, Amstutz U, Jetter A, Samer CF, **Ansari M**.  
*Grundlagen und praktische Hinweise für pharmakogenetische Tests: Personalisierte Therapie bei Psychopharmaka = Notions de base et aspects pratiques à propos de tests pharmacogénétiques : pharmacogénomique et thérapie personnalisée.*  
InFo Neurologie und Psychiatrie, vol. 15 (2017), No 6, pp. 21-30
134. Baumann P, Amstutz U, Bühlmann RP, Meier-Abt P, Meyer UA, Samer C, **Ansari M**.  
*Pharmacogénomique et thérapie personnalisée.*  
Rev Med Suisse, vol. 13 (2017), No pp. 1544-1545
135. Balduzzi A, Dalle JH, Jahnukainen K, von Wolff M, Lucchini G, Ifversen M, Macklon KT, Poirot C, Diesch T, Jarisch A, Bresters D, Yaniv I, Gibson B, Willasch AM, Fadini R, Ferrari L, Lawitschka A, Ahler A, Sanger N, Corbacioglu S, **Ansari M**, Moffat R, Dalissier A, Beohou E, Sedlacek P, Lankester A, De Heredia Rubio CD, Vetterranta K, Wachowiak J, Yesilipek A, Trigosso E, Klingebiel T, Peters C, Bader P.

*Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group.*  
Bone Marrow Transplant, vol. 52 (2017), No 10, pp. 1406-1415

136. **Ansari M, Curtis PH, Uppugunduri CRS, Rezgui MA, Nava T, Mlakar V, Lesne L, Theoret Y, Chalandon Y, Dupuis LL, Schechter T, Bartelink IH, Boelens JJ, Bredius R, Dalle JH, Azarnoush S, Sedlacek P, Lewis V, Champagne M, Peters C, Bittencourt H, Krajcinovic M.**  
*GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation : a multicenter study.*  
Oncotarget, vol. 8 (2017), No 53, pp. 90852-90867
137. Amstutz U, **Mlakar V, Curtis PH**, Samer C, Baumann P, Buhlmann RP, Meier-Abt P, Meyer UA, van Schaik RHN, **Ansari M.**  
*Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT).*  
Drug Metab Pers Ther, vol. 32 (2017), No 4, pp. 173-174
138. Veldhuijzen van Zanten SEM, Baugh J, Chaney B, De Jongh D, Sanchez Aliaga E, Barkhof F, Noltes J, De Wolf R, Van Dijk J, Cannarozzo A, Damen-Korbijn CM, Lieverst JA, Colditz N, Hoffmann M, Warmuth-Metz M, Bison B, Jones DTW, Sturm D, Gielen GH, Jones C, Hulleman E, Calmon R, Castel D, Varlet P, Giraud G, Slavc I, Van Gool S, Jacobs S, Jadrijevic-Cvrle F, Sumerauer D, Nysom K, Pentikainen V, Kivivuori SM, Leblond P, Entz-Werle N, **von Bueren AO**, Kattamis A, Hargrave DR, Hauser P, Garami M, Thorarinsdottir HK, Pears J, Gandola L, Rutkauskiene G, Janssens GO, Torsvik IK, Perek-Polnik M, Gil-da-Costa MJ, Zheludkova O, Shats L, Deak L, Kitanovski L, Cruz O, Morales La Madrid A, Holm S, Gerber N, Kebudi R, Grundy R, Lopez-Aguilar E, Zapata-Tarres M, Emmerik J, Hayden T, Bailey S, Biassoni V, Massimino M, Grill J, Vandertop WP, Kaspers GJL, Fouladi M, Kramm CM, van Vuurden DG.  
*Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease.*  
J Neurooncol. (2017). Vol. 132, No. 2, pp.255-66
139. Ripperger T, Bielack SS, Borkhardt A, Brecht IB, Burkhardt B, Calaminus G, Debatin KM, Deubzer H, Dirksen U, Eckert C, Eggert A, Erlacher M, Fleischhack G, Fruhwald MC, Gnekow A, Goehring G, Graf N, Hanenberg H, Hauer J, Hero B, Hettmer S, von Hoff K, Horstmann M, Hoyer J, Illig T, Kaatsch P, Kappler R, Kerl K, Klingebiel T, Kontny U, Kordes U, Korholz D, Koscielniak E, Kramm CM, Kuhlen M, Kulozik AE, Lamottke B, Leuschner I, Lohmann DR, Meinhardt A, Metzler M, Meyer LH, Moser O, Nathrath M, Niemeyer CM, Nustede R, Pajtler KW, Paret C, Rasche M, Reinhardt D, Riess O, Russo A, Rutkowski S, Schlegelberger B, Schneider D, Schneppenheim R, Schrappe M, Schroeder C, von Schweinitz D, Simon T, Sparber-Sauer M, Spix C, Stanulla M, Steinemann D, Strahm B, Temming P, Thomay K, **von Bueren AO**, Vorwerk P, Witt O, Wlodarski M, Wossmann W, Zenker M, Zimmermann S, Pfister SM, Kratz CP.  
*Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology.*  
Am J Med Genet A. (2017). Vol. 173, No. 4, pp.1017-37
140. Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, Bjerke L, Clarke M, Vinci M, Nandhabalan M, Temelso S, Popov S, Molinari V, Raman P, Waanders AJ, Han HJ, Gupta S, Marshall L, Zacharoulis S, Vaidya S, Mandeville HC, Bridges LR, Martin AJ, Al-Sarraj S, Chandler C, Ng HK, Li X, Mu K, Trabelsi S, Brahim DH, Kisljakov AN, Konovalov DM, Moore AS, Carcaboso AM, Sunol M, de Torres C, Cruz O, Mora J, Shats LI, Stavale JN, Bidinotto LT, Reis RM, Entz-Werle N, Farrell M, Cryan J, Crimmins D, Caird J, Pears J, Monje M, Debily MA, Castel D, Grill J, Hawkins C, Nikbakht H, Jabado N, Baker SJ, Pfister SM, Jones DTW, Fouladi M, **von Bueren AO**, Baudis M, Resnick A, Jones C.  
*Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma.*  
Cancer Cell. (2017). Vol. 32, No. 4, pp.520-37.e5
141. Kodidela S, Suresh SK, **Uppugunduri CRS.**  
*Developmental pattern of hepatic drug-metabolizing enzymes in pediatric population and its role in optimal drug treatment.*  
Archives of Medicine and Health Sciences. (2017). Vol. No. pp.115-22
142. Karremann M, Kramer N, Hoffmann M, Wiese M, Beilken A, Corbacioglu S, Dilloo D, Driever PH, Scheurlen W, Kulozik A, Gielen GH, **von Bueren AO**, Durken M, Kramm CM.  
*Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.*  
Eur J Cancer. (2017). Vol. 81, No. pp.1-8

143. Janssens GO, Gandola L, Bolle S, Mandeville H, Ramos-Albiac M, van Beek K, Benghiat H, Hoeben B, Morales La Madrid A, Kortmann RD, Hargrave D, Menten J, Pecori E, Biassoni V, **von Bueren AO**, van Vuurden DG, Massimino M, Sturm D, Peters M, Kramm CM.  
*Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group.*  
Eur J Cancer. (2017). Vol. 73, No. pp.38-47
144. Hutter G, Sailer M, Azad TD, **von Bueren AO**, Nollau P, Frank S, Tostado C, Sarvepalli D, Ghosh A, Ritz MF, Boulay JL, Mariani L.  
*Reverse phase protein arrays enable glioblastoma molecular subtyping.*  
J Neurooncol. (2017). Vol. 131, No. 3, pp.437-48
145. Friedrich C, Shalaby T, Oehler C, Pruschy M, Seifert B, Picard D, Remke M, Warmuth-Metz M, Kortmann RD, Rutkowski S, Grotzer MA, **von Bueren AO**.  
*Tropomyosin receptor kinase C (TrkC) expression in medulloblastoma: relation to the molecular subgroups and impact on treatment response.*  
Childs Nerv Syst. (2017). Vol. 33, No. 9, pp.1463-71

## 2016

146. Zimmermann K, Bergstraesser E, Engberg S, Ramelet AS, Marfurt-Russenberger K, Von der Weid N, Grandjean C, Fahrni-Nater P, Cignacco E, PELICAN Consortium (dont **Ansari M**).  
*When parents face the death of their child: a nationwide cross-sectional survey of parental perspectives on their child's end-of life care.*  
BMC Palliat Care, vol. 15 (2016), No pp. 30
147. Wangmo T, Ruhe KM, Badarau DO, Kuhne T, Niggli F, Elger BS, Swiss paediatric oncology group (SPOG) (dont **Ansari M**).  
*Parents' and patients' experiences with paediatric oncology care in Switzerland--satisfaction and some hurdles.*  
Swiss Med Wkly, vol. 146 (2016), No pp. w14309
148. **Von Bueren A**, Ares C, Bartoli A, Fluss J, Girardin C, Migliorini D, Merlini L, Merkler D, **Ansari M**.  
*Medulloblastoma in children and adults : One distinct disease entity ?*  
Bulletin suisse du cancer Schweizer Krebsbulletin, vol. 2 (2016), No pp. 158-161
149. **Uppugunduri CR, Ansari M**.  
*Commentary : A Myriad Aberrations on Information of Ontogeny of Drug Metabolizing Enzymes in the Pediatric Population: An Obstacle for Personalizing Drug Therapy in the Pediatric Population.*  
Drug Metab Lett, vol. 10 (2016), No 2, pp. 72-74
150. Schluckebier D, McLin VA, Kanavaki I, **Ansari M**, Wildhaber BE.  
*The Role of Liver Transplantation in Undifferentiated Embryonal Sarcoma of the Liver in Children.*  
J Pediatr Hematol Oncol, vol. 38 (2016), No 6, pp. 495-496
151. Schindler M, Spycher BD, Ammann RA, **Ansari M**, Michel G, Kuehni CE.  
*Cause-specific long-term mortality in survivors of childhood cancer in Switzerland : A population-based study.*  
Int J Cancer, vol. 139 (2016), No 2, pp. 322-333
152. Ruhe KM, Wangmo T, De Clercq E, Badarau DO, **Ansari M**, Kuhne T, Niggli F, Elger BS.  
*Putting patient participation into practice in pediatrics-results from a qualitative study in pediatric oncology.*  
Eur J Pediatr, vol. 175 (2016), No 9, pp. 1147-1155
153. Ruhe KM, Badarau DO, Brazzola P, Hengartner H, Elger BS, Wangmo T, for the Swiss Pediatric Oncology Group (SPOG) (dont **Ansari M**).  
*Participation in pediatric oncology: views of child and adolescent patients.*  
Psychooncology, vol. 25 (2016), No 9, pp. 1036-1042
154. **Mlakar V, Huezo-Diaz Curtis P, Satyanarayana Uppugunduri CR**, Krajinovic M, **Ansari M**.  
*Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use.*  
Int J Mol Sci, vol. 17 (2016), No 9

155. **Mlakar V, Huezo Diaz Curtis P, Baumann P, Bühlmann RP, Meier-Abt P, Meyer UA, Ansari M.**  
*Création du Groupe Suisse de Pharmacogénomique et de Thérapie Personnalisée.*  
Bulletin suisse du cancer, Schweizer Krebsbulletin, vol. 2 (2016), No pp. 264
156. Michel G, Gianinazzi ME, Eiser C, Bergstrasser E, Vetsch J, von der Weid N, Kuehni CE, for the Swiss Pediatric Oncology Group (SPOG) (dont **Ansari M**).  
*Preferences for long-term follow-up care in childhood cancer survivors.*  
Eur J Cancer Care (Engl), vol. 25 (2016), No 6, pp. 1024-1033
157. Manolopoulos VG, Van Schaik RHN, Visvikis-Siest S, Marc J, Simmaco M, Jacobs P, Cascorbi I, **Ansari M, LLerena A.**  
*In Memoriam Gérard Siest.*  
Drug Metabolism and Personalized Therapy, vol. 31 (2016), No 2, pp. 59
158. Mader L, Rueegg CS, Vetsch J, Rischewski J, **Ansari M, Kuehni CE, Michel G.**  
*Employment Situation of Parents of Long-Term Childhood Cancer Survivors.*  
PLoS One, vol. 11 (2016), No 3, pp. e0151966
159. Lupatsch JE, Wengenroth L, Rueegg CS, Teuffel O, **Gumy-Pause F, Kuehni CE, Michel G, Swiss Paediatric Oncology Group (dont Ansari M).**  
*Follow-up care of adolescent survivors of childhood cancer: The role of health beliefs.*  
Pediatr Blood Cancer, vol. 63 (2016), No 2, pp. 318-325
160. Krajinovic M, Elbared J, Drouin S, Bertout L, Rezgui A, **Ansari M, Raboisson MJ, Lipshultz SE, Silverman LB, Sallan SE, Neuberger DS, Kutok JL, Laverdiere C, Sinnott D, Andelfinger G.**  
*Polymorphisms of ABCG5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.*  
Pharmacogenomics J, vol. 16 (2016), No 6, pp. 530-535
161. **Huezo-Diaz P, Uppugunduri CR, Ansari M.**  
*Potential Predictive Biomarkers used to optimize treatments for Sinusoidal Obstruction Syndrome in pediatric Hematopoietic stem cell transplantation.*  
Bulletin suisse du cancer Schweizer Krebsbulletin, vol. 4 (2016), No pp. 349-352
162. Bresters D, Lawitschka A, Cugno C, Potschger U, Dalissier A, Michel G, Vettenranta K, Sundin M, Al-Seraihy A, Faraci M, Sedlacek P, Versluys AB, Jenkins A, Lutz P, Gibson B, Leiper A, Diaz MA, Shaw PJ, Skinner R, O'Brien TA, Salooja N, Bader P, Peters C, on behalf of the Pediatric Working disease of EBMT (dont **Ansari M**).  
*Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters.*  
Bone Marrow Transplant, vol. 51 (2016), No 11, pp. 1482-1489
163. Beauverd Y, Roosnek E, Tirefort Y, Dantin C, **Ansari M, Tsopra O, Masouridi-Levrat S, Chalandon Y.**  
*Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index.*  
Bone Marrow Transplant, vol. 51 (2016), No 7, pp. 955-960
164. Baumann P, Bühlmann RP, Jetter A, Kupferschmidt H, Meier-Abt P, Meyer UA, **Ansari A.**  
*Création du Groupe Suisse de Pharmacogénomique et de Thérapie Personnalisée (SPT).*  
Pipette-Swiss laboratory Medecine, vol. (2016), No 3, pp. 17-18
165. Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, **Ansari M, Krajinovic M, Theoret Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Gungor T, Wynn RF, Veys P, Cuvelier GD, Markt S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ.**  
*Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.*  
Lancet Haematol, vol. 3 (2016), No 11, pp. e526-e536
166. **Ansari M, Huezo-Diaz P, Rezgui MA, Markt S, Duval M, Bittencourt H, Cappelli B, Krajinovic M.**  
*Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients.*  
Bone Marrow Transplant, vol. 51 (2016), No 3, pp. 377-383
167. **Ansari M.**



168. Adam M, Rueegg CS, Schmidlin K, Spoerri A, Niggli F, Grotzer M, von der Weid NX, Egger M, Probst-Hensch N, Zwahlen M, Kuehni CE, Swiss Paediatric Oncology Group, Swiss National Cohort Study (dont **Ansari M**).  
*Socioeconomic disparities in childhood cancer survival in Switzerland.*  
Int J Cancer, vol. 138 (2016), No 12, pp. 2856-2866
169. Acosta-Martin AE, Antinori P, **Uppugunduri CRS**, Daali Y, **Ansari M**, Scherl A, Muller M, Lescuyer P.  
*Detection of busulfan adducts on proteins.*  
Rapid Commun Mass Spectrom, vol. 30 (2016), No 23, pp. 2517-2528
170. Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, Boudalil M, Previti C, Wolf S, Schmidt S, Chotewutmontri S, Bewerunge-Hudler M, Schick M, Schlesner M, Hutter B, Taylor L, Borst T, Sutter C, Bartram CR, Milde T, Pfaff E, Kulozik AE, von Stackelberg A, Meisel R, Borkhardt A, Reinhardt D, Klusmann JH, Fleischhack G, Tippelt S, Dirksen U, Jurgens H, Kramm CM, **von Bueren AO**, Westermann F, Fischer M, Burkhardt B, Wossmann W, Nathrath M, Bielack SS, Fruhwald MC, Fulda S, Klingebiel T, Koscielniak E, Schwab M, Tremmel R, Driever PH, Schulte JH, Brors B, von Deimling A, Lichter P, Eggert A, Capper D, Pfister SM, Jones DT, Witt O.  
*Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.*  
Eur J Cancer. (2016). Vol. 65, No. pp.91-101
171. **Uppugunduri CR, Ansari M.**  
*Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition--The Dream of Translational Medicine.*  
J Cardiovasc Pharmacol. (2016). Vol. 67, No. 2, pp.191-2
172. Friedrich C, **von Bueren AO**, Kolevatova L, Bernreuther C, Grob T, Sepulveda-Falla D, van den Boom L, Westphal M, Simon R, Glatzel M.  
*Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma.*  
Childs Nerv Syst. (2016). Vol. 32, No. 2, pp.281-90
173. Dietl S, Schwinn S, Dietl S, Riedel S, Deinlein F, Rutkowski S, **von Bueren AO**, Krauss J, Schweitzer T, Vince GH, Picard D, Eyrich M, Rosenwald A, Ramaswamy V, Taylor MD, Remke M, Monoranu CM, Beilhack A, Schlegel PG, Wolf M.  
*MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties.*  
BMC Cancer. (2016). Vol. 16, No. pp.115
174. Bosilkovska M, Ing Lorenzini K, **Uppugunduri CR**, Desmeules J, Daali Y, Escher M.  
*Severe Vincristine-induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study.*  
Clin Ther. (2016). Vol. 38, No. 1, pp.216-20

## 2015

175. von Laer Tschudin L, Schwitzgebel VM, von Scheven-Gete A, Blouin JL, Hofer M, Hauschild M, **Ansari M**, Stoppa-Vaucher S, Phan-Hug F.  
*Diabetes and immune thrombocytopenic purpura : a new association with good response to anti-CD20 therapy.*  
Pediatr Diabetes, vol. 16 (2015), No 2, pp. 138-145
176. Siest G, Auffray C, Taniguchi N, Ingelman-Sundberg M, Murray H, Visvikis-Siest S, **Ansari M**, Marc J, Jacobs P, Meyer U, Van Schaik RH, Muller MM, Wevers RA, Simmaco M, Kussmann M, Manolopoulos VG, Alizadeh BZ, Bealstall G, Nemeth G.  
*Systems medicine, personalized health and therapy.*  
Pharmacogenomics, vol. 16 (2015), No 14, pp. 1527-1539
177. Schindler M, Mitter V, Bergstraesser E, Gumy-Pause F, Michel G, Kuehni CE, Swiss paediatric oncology group (SPOG) (dont **Ansari M**).  
*Death certificate notifications in the Swiss Childhood Cancer Registry: assessing completeness and registration procedures.*  
Swiss Med Wkly, vol. 145 (2015), No pp. w14225
178. Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N, SIOP Renal Tumours Study Group (dont **Ansari M**).

- Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.*  
Lancet, vol. 386 (2015), No 9999, pp. 1156-1164
179. **Mandriota SJ**, Valentijn LJ, **Lesne L**, Betts DR, **Marino D**, **Boudal-Khoshbeen M**, London WB, Rougemont AL, Attiyeh EF, Maris JM, Hogarty MD, Koster J, Molenaar JJ, Versteeg R, **Ansari M**, **Gumy-Pause F**.  
*Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism.*  
Oncotarget, vol. 6 (2015), No 21, pp. 18558-18576
180. Levrat E, Roosnek E, Masouridi S, Mohty B, **Ansari M**, Villard J, Passweg JR, Chalandon Y.  
*Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies.*  
Bone Marrow Res, vol. 2015 (2015), No pp. 176526
181. Lawitschka A, Faraci M, Yaniv I, Veys P, Bader P, Wachowiak J, Socie G, Aljurf MD, Arat M, Boelens JJ, Duarte R, Tichelli A, Peters C, (dont **Ansari M**).  
*Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.*  
Bone Marrow Transplant, vol. 50 (2015), No 4, pp. 592-597
182. Lalmohamed A, Bartelink I, van Reij L, Dvorak CC, Savic R, Zwaveling J, Bredius R, Egberts A, Bierings M, Kletzel M, Shaw P, Nath C, Hempel G, **Ansari M**, Krajinovic M, Gungor T, Wynn RF, Veys P, Cuvelier G, Chiesa R, Slatter M, Long-Boyle J, Boelens J.  
*Studying the Optimal Intravenous Busulfan Exposure in Pediatric Allogeneic Hematopoietic Cell Transplantation (alloHCT) to Improve Clinical Outcomes: A Multicenter Study.*  
Biology of Blood and Marrow Transplantation, vol. 21 (2015), No 2, Supplement, pp. S102-S103
183. Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Papai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kuhne T, Jurgens H, van den Berg H, Bohling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M, EURAMOS-1 investigators (dont **Ansari M**).  
*Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.*  
J Clin Oncol, vol. 33 (2015), No 20, pp. 2279-2287
184. Arni D, **Gumy-Pause F**, **Ansari M**, Kremer Hovinga JA, McLin VA.  
*Successful liver transplantation in a child with acute-on-chronic liver failure and acquired thrombotic thrombocytopenic purpura.*  
Liver Transpl, vol. 21 (2015), No 5, pp. 704-706
185. **Ansari M**, Steck V.  
*La Fondation CANSEARCH se bat pour les enfants atteints de cancer.*  
Planète santé (2015)
186. **Ansari M**, Maibach R, on behalf of the Kids Liver CANSEARCH Group.  
*Hepatoblastoma in Switzerland.*  
Bulletin suisse du cancer, Krebsbulletin, vol. 3 (2015), No pp. 241-242
187. Veys PA, Nanduri V, Baker KS, He W, Bandini G, Biondi A, Dalissier A, Davis JH, Eames GM, Egeler RM, Filipovich AH, Fischer A, Jürgens H, Krance R, Lanino E, Leung WH, Matthes S, Michel G, Orchard PJ, Pieczonka A, Ringdén O, Schlegel PG, Sirvent A, Vettenranta K, Eapen M, (dont **Ansari M**).  
*Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning.*  
Br J Haematol. (2015). Vol. 169, No. 5, pp.711-8
188. Lawitschka A, Faraci M, Yaniv I, Veys P, Bader P, Wachowiak J, Socie G, Aljurf MD, Arat M, Boelens JJ, Duarte R, Tichelli A, Peters C, (dont **Ansari M**).  
*Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.*  
Bone Marrow Transplant. (2015). Vol. 50, No. 4, pp.592-7

2014

189. Carneseccchi S, Rougemont AL, Doroshov JH, Nagy M, Mouche S, **Gumy-Pause F**, Szanto I.  
*The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines.*  
Free Radic Biol Med. (2015). Vol. 84, No. pp.22-9
190. Wengenroth L, Rueegg CS, Michel G, Essig S, Ammann RA, Bergstraesser E, Kuehni CE, for the Swiss paediatric oncology group (SPOG) (dont **Ansari M**).  
*Life partnerships in childhood cancer survivors, their siblings, and the general population.*  
Pediatr Blood Cancer, vol. 61 (2014), No 3, pp. 538-545
191. **Uppugunduri CR**, Rezgui MA, **Diaz PH**, Tyagi AK, Rousseau J, Daali Y, Duval M, Bittencourt H, Krajinovic M, **Ansari M**.  
*The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation.*  
Pharmacogenomics J, vol. 14 (2014), No 3, pp. 263-271
192. Tyagi AK, **Huezo-Diaz P**, **Ansari M**.  
*Personalizing busulfan therapy for children undergoing hematopoietic stem cell transplantation.*  
Per Med, vol. 11 (2014), No 5, pp. 463-466
193. Rock N, **Mattiello V**, Judas C, **Huezo-Diaz P**, Bourquin JP, **Gumy-Pause F**, **Ansari M**.  
*Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.*  
Pediatr Hematol Oncol, vol. 31 (2014), No 2, pp. 143-148
194. Rischewski J, **Ansari M**, all of the head SPOG station.  
*Pediatric Oncology in Switzerland : Infrastructure and Results.*  
Bulletin suisse du cancer, Schweizer Krebsbulletin, vol. 3 (2014), No pp. 219-224
195. Montaruli E, Wildhaber BE, **Ansari M**, Birraux J.  
*Adenovirus-induced obstructive uropathy with acute renal failure in an immunodeficient child.*  
Urology, vol. 83 (2014), No 1, pp. 217-219
196. Marek A, Stern M, Chalandon Y, **Ansari M**, Ozsahin H, Gungor T, Gerber B, Kuhne T, Passweg JR, Gratwohl A, Tichelli A, Seger R, Schanz U, Halter J, Stussi G.  
*The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT.*  
Bone Marrow Transplant, vol. 49 (2014), No 1, pp. 55-61
197. **Huezo-Diaz P**, **Uppugunduri CR**, Tyagi AK, Krajinovic M, **Ansari M**.  
*Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in children.*  
Curr Drug Metab, vol. 15 (2014), No 3, pp. 251-264
198. Hauri DD, Spycher B, Huss A, Zimmermann F, Grotzer M, von der Weid N, Spoerri A, Kuehni CE, Roosli M, and Swiss national cohort, and Swiss paediatric oncology group (dont **Ansari M**).  
*Exposure to radio-frequency electromagnetic fields from broadcast transmitters and risk of childhood cancer: a census-based cohort study.*  
Am J Epidemiol, vol. 179 (2014), No 7, pp. 843-851
199. Gianinazzi ME, Rueegg CS, von der Weid NX, Niggli FK, Kuehni CE, Michel G, and Swiss paediatric oncology group (SPOG) (dont **Ansari M**).  
*Mental health-care utilization in survivors of childhood cancer and siblings: the Swiss childhood cancer survivor study.*  
Support Care Cancer, vol. 22 (2014), No 2, pp. 339-349
200. Gianinazzi ME, Essig S, Rueegg CS, von der Weid NX, Brazzola P, Kuehni CE, Michel G, Swiss Paediatric Oncology Group (SPOG) (dont **Ansari M**).  
*Information provision and information needs in adult survivors of childhood cancer.*  
Pediatr Blood Cancer, vol. 61 (2014), No 2, pp. 312-318
201. Beauverd Y, Roosnek E, Tirefort Y, Nagy-Hulliger M, Bernimoulin M, Tsopra O, **Ansari M**, Dantin C, Casini A, Grandjean AP, Chigrinova E, Masouridi-Levrat S, Chalandon Y.  
*Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion.*  
Biol Blood Marrow Transplant, vol. 20 (2014), No 9, pp. 1322-1328

202. **Ansari M**, Theoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne MA, Duval M, Krajinovic M, Bittencourt H.  
*Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.*  
Ther Drug Monit, vol. 36 (2014), No 1, pp. 93-99

## 2013

203. Tyagi AK, **Uppugunduri CR**, P. H-D, Krajinovic M, **Ansari M**.  
*Can pharmacogenetics and pharmacokinetics of busulfan be used to individualize treatment for children undergoing hematopoietic stem cell transplantation ?*  
Bulletin suisse du cancer, Krebsbulletin vol. 4 (2013), No pp. 323-326
204. Tyagi AK, Pradier A, Baumer O, **Uppugunduri CR**, **Huezo-Diaz P**, Posfay-Barbe K, Roosnek E, **Ansari M**.  
*Validation of SYBR Green based quantification assay for the detection of human Torque Teno virus titers from plasma.*  
Virol J, vol. 10 (2013), No pp. 191
205. Rueegg CS, Gianinazzi ME, Michel G, von der Weid NX, Bergstraesser E, Kuehni CE, and Swiss paediatric oncology group (SPOG) (dont **Ansari M**).  
*Do childhood cancer survivors with physical performance limitations reach healthy activity levels ?*  
Pediatr Blood Cancer, vol. 60 (2013), No 10, pp. 1714-1720
206. Ligue genevoise contre le cancer, (dont **Ansari M**).  
*L'enfant face au cancer: une sélection de livres, de vidéos et de sites web pour les 3-16 ans et leurs parents.*  
Université de Genève, Faculté de médecine, Centre de documentation en santé (2013)
207. Labarinas S, **Gumy-Pause F**, Rougemont AL, Baerlocher G, Leibundgut EO, Porret N, Schappi MG, Barazzone-Argiroffo C, Passweg J, Merlini L, Ozsahin H, **Ansari M**.  
*Is acute fibrinous and organizing pneumonia the expression of immune dysregulation ?*  
J Pediatr Hematol Oncol, vol. 35 (2013), No 2, pp. 139-143
208. Korchi AM, Garibotto V, **Ansari M**, Merlini L.  
*Pseudoprogression after proton beam irradiation for a choroid plexus carcinoma in pediatric patient: MRI and PET imaging patterns.*  
Childs Nerv Syst, vol. 29 (2013), No 3, pp. 509-512
209. Hauri D, Spycher B, Huss A, Zimmermann F, Grotzer M, von der Weid N, Weber D, Spoerri A, Kuehni CE, Roosli M, and Swiss national cohort, and Swiss paediatric oncology group (SPOG) (dont **Ansari M**).  
*Domestic radon exposure and risk of childhood cancer: a prospective census-based cohort study.*  
Environ Health Perspect, vol. 121 (2013), No 10, pp. 1239-1244
210. Gollut S, Stückelberger S, Meier S, Mamie C, Humbert N, **Ansari M**.  
*Suivi des familles après le décès d'un enfant en oncobématologie pédiatrique : un besoin ?*  
Médecine Palliative : Soins de Support - Accompagnement - Éthique, vol. 12 (2013), No 3, pp. 112-121
211. Ceschi A, Rauber-Luthy C, Kupferschmidt H, Banner NR, **Ansari M**, Krahenbuhl S, Taegtmeier AB.  
*Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011.*  
Am J Transplant, vol. 13 (2013), No 3, pp. 786-795
212. **Ansari M**, **Uppugunduri CR**, Ferrari-Lacraz S, Bittencourt H, **Gumy-Pause F**, Chalandon Y, Tiercy JM, Schechter T, Gassas A, Doyle JD, Dupuis L, Duval M, Krajinovic M, Villard J.  
*The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children.*  
PLoS One, vol. 8 (2013), No 8, pp. e72141
213. **Ansari M**, Rezgui MA, Theoret Y, **Uppugunduri CR**, Mezziani S, Vachon MF, Desjean C, Rousseau J, Labuda M, Przybyla C, Duval M, Champagne M, Peters C, Bittencourt H, Krajinovic M.  
*Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients.*  
Bone Marrow Transplant, vol. 48 (2013), No 7, pp. 939-946

214. **Ansari M.**  
*Pharmacogenetic aspect of busulfan based conditioning regimens prior to allogenic hematopoietic stem cell transplantation in children 2013.*  
Université de Genève. Thèse de privat-docent, 2013

## 2012

215. von der Weid NX, **Ansari M.**  
*Pediatric hemato-oncology: from cellular biology to individualized targeted therapies.*  
Rev Med Suisse, vol. 8 (2012), No 329, pp. 403-404, 406-408
216. Versace F, **Uppugunduri CR**, Krajinovic M, Theoret Y, **Gumy-Pause F**, Mangin P, Staub C, **Ansari M.**  
*A novel method for quantification of sulfolane (a metabolite of busulfan) in plasma by gas chromatography-tandem mass spectrometry.*  
Anal Bioanal Chem, vol. 404 (2012), No 6-7, pp. 1831-1838
217. **Uppugunduri CR**, Daali Y, Desmeules J, Dayer P, Krajinovic M, **Ansari M.**  
*Transcriptional regulation of CYP2C19 and its role in altered enzyme activity.*  
Curr Drug Metab, vol. 13 (2012), No 8, pp. 1196-1204
218. **Uppugunduri CR, Ansari M.**  
*Influence of age, sex, and haplotypes of thiopurine methyltransferase (TPMT) gene on 6-mercaptopurine toxicity in children with acute lymphoblastic leukemia.*  
Eur J Clin Pharmacol, vol. 68 (2012), No 5, pp. 887-888; author reply 885-886
219. **Gumy-Pause F**, Pardo B, **Khoshbeen-Boudal M, Ansari M**, Gayet-Ageron A, Sappino AP, Attiyeh EF, Ozsahin H.  
*GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma.*  
Genes Chromosomes Cancer, vol. 51 (2012), No 2, pp. 174-185
220. **Ansari M, Uppugunduri CR**, Deglon J, Theoret Y, Versace F, **Gumy-Pause F**, Ozsahin H, Dayer P, Desmeules J, Daali Y.  
*A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry.*  
Rapid Commun Mass Spectrom, vol. 26 (2012), No 12, pp. 1437-1446
221. **Ansari M**, Strunk D, Schallmoser K, Delco C, Rougemont AL, Moll S, Villard J, **Gumy-Pause F**, Chalandon Y, Parvex P, Passweg J, Ozsahin H, Kindler V.  
*Third-party mesenchymal stromal cell infusion is associated with a decrease in thrombotic microangiopathy symptoms observed post-hematopoietic stem cell transplantation.*  
Pediatr Transplant, vol. 16 (2012), No 2, pp. 131-136
222. **Ansari M**, Sauty G, Labuda M, Gagne V, Rousseau J, Moghrabi A, Laverdiere C, Sinnott D, Krajinovic M.  
*Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia.*  
Pharmacogenomics J, vol. 12 (2012), No 5, pp. 386-394
223. **Ansari M**, Rougemont AL, Le Deist F, Ozsahin H, Duval M, Champagne MA, Fournet JC.  
*Secondary pulmonary alveolar proteinosis after unrelated cord blood hematopoietic cell transplantation.*  
Pediatr Transplant, vol. 16 (2012), No 5, pp. E146-149
224. Sappino AP, Buser R, Seguin Q, Fernet M, **Lesne L, Gumy-Pause F**, Reith W, Favaudon V, **Mandriota SJ.**  
*The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damage.*  
Oncogenesis. (2012). Vol. 1, No. pp.e7
225. Sappino AP, Buser R, **Lesne L**, Gimelli S, Bena F, Belin D, **Mandriota SJ.**  
*Aluminium chloride promotes anchorage-independent growth in human mammary epithelial cells.*  
J Appl Toxicol. (2012). Vol. 32, No. 3, pp.233-43

226. Brunsvig KL, Zenobi M, Rilliet B, El Hassani Y, de Haller R, **Ansari M**, Lobrinus JA, Hanquinet S, Fluss J.  
*Primary leptomeningeal melanocytosis in a 10-year-old girl: a challenging diagnosis with a poor prognosis.*  
J Child Neurol, vol. 26 (2011), No 11, pp. 1444-1448
227. Bieri S, Roosnek E, Ozsahin H, Huguet S, **Ansari M**, Trombetti A, Helg C, Chapuis B, Miralbell R, Passweg J, Chalandon Y.  
*Outcome and risk factors for late-onset complications 24 months beyond allogeneic hematopoietic stem cell transplantation.*  
Eur J Haematol, vol. 87 (2011), No 2, pp. 138-147
228. **Ansari M**, Vukicevic M, Rougemont AL, Moll S, Parvex P, **Gumy-Pause F**, Chalandon Y, Passweg J, Ozsahin H, Roosnek E.  
*Do NK cells contribute to the pathophysiology of transplant-associated thrombotic microangiopathy ?*  
Am J Transplant, vol. 11 (2011), No 8, pp. 1748-1752
229. **Ansari M**, Gollut S, Stuckelberger S.  
*Faut-il un suivi des familles après le décès d'un enfant en oncologie pédiatrique ?*  
Réseau francophone de soins palliatifs pédiatriques, (2011)
230. Weber DC, Zilli T, Do HP, Nouet P, **Gumy Pause F**, Pica A.  
*Intensity modulated radiation therapy or stereotactic fractionated radiotherapy for infratentorial ependymoma in children: a multicentric study.*  
J Neurooncol. (2011). Vol. 102, No. 2, pp.295-300
231. **Gumy-Pause F**, Ozsahin H, Turello R, Girardin C, Phan-Hug F, Wunder D, Primi MP, Simon JP, Schwitzgebel V, Beck-Popovic M, Bellavia M, Ambrosetti A, Yaron M.  
*Female fertility preservation in paediatric cancer patients: a multidisciplinary approach.*  
Bulletin suisse du cancer. (2011). Vol. 31, No. pp.321-4